This discussion focuses on how mRNA and self-replicating RNA (srRNA) technologies are expanding far beyond COVID vaccines into revolutionary therapeutic applications for cancer and rare diseases. It is clear that mRNA therapeutics offer three major application areas: infectious disease vaccines, therapeutic vaccines for oncology, and protein replacement for monogenic rare diseases.

Today’s episode is sponsored by Eclipsebio. From AI-ready datasets to sequencing validation, they drive RNA success.

Explore their solutions at https://eclipsebio.com/.

Host

⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

Andy Geall, Co-founder and Chief Development Officer, Replicate Bioscience; Chair of the Board, Alliance for mRNA Medicines

Pad Chivukula, Co-founder, CSO & COO, Arcturus Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines

BioSpace